Deciphera Pharmaceuticals, LLC
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2017 | $52 M | No. 2 | $50 to $250 million | equity | SEC | |
| Sep 2015 | $91 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Deciphera Pharmaceuticals, LLC chose not to state its revenue in its newest notice of a funding round (Jun 2017).
SEC Form D · Jun 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2017
That is all the official record says: Deciphera Pharmaceuticals, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Brightstar Associates LLC | Other | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Leaf Biopharma Opportunities I, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Leaf BPO Associates I, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Leaf Venture Associates III, L.P. | Venture capital | not stated | not stated | Held Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Leaf Venture Management III, L.L.C. | Venture capital | not stated | not stated | Held Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Leaf Ventures III, L.P. | Venture capital | not stated | not stated | Held Series B-1, B-2 and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher J. Morl | Executive officer | Jun 2017 |
| Daniel L. Flynn, Ph.D. | Executive officer | Jun 2017 |
| Michael D. Taylor, Ph.D. | Executive officer | Jun 2017 |
| Oliver L. Rosen, M.D. | Executive officer | Jun 2017 |
| Thomas L. Kelly | Executive officer | Jun 2017 |
| Daniel F. Flynn, Ph.D. | Executive officer | Jul 2016 |
| Michael Taylor | Executive officer | Jul 2016 |
| Oliver F. Rosen, M.D. | Executive officer | Jul 2016 |
| Thomas F. Kelly | Executive officer | Jul 2016 |
| Dennis A. Walsh | Director | Jun 2017 |
| Edward J. Benz, Jr. | Director | Jun 2017 |
| James A. Bristol, Ph.D. | Director | Jun 2017 |
| John A. Martin | Director | Jun 2017 |
| Liam A. Ratcliffe, M.D., Ph.D. | Director | Jun 2017 |
| Michael A. Ross | Director | Jun 2017 |
| Michael D. Taylor, Ph.D. | Director | Jun 2017 |
| Patricia L. Allen | Director | Jun 2017 |
| Michael Taylor | Director | Jul 2016 |